The human microbiome, a dynamic endocrine organ, exerts profound systemic influence through the production of bioactive metabolites. While the microbiome-gut-brain axis is well-established, the direct conduit between the gut microbiota …
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet sex-specific risk factors are usually not included in conventional predictive models. Specifically, heart failure (HF) in women may …
Endometriosis presents a multitude of challenges for individuals. Current treatment of the disease is based on pharmacotherapy that aims to relieve pain, improves future fertility, potentially slows disease progression and …
It is critical that women undertaking medically assisted reproductive (MAR) treatment and their clinicians know whether the treatments are associated with an increased risk of hormone-related cancers.
Buserelin, a gonadotropin-releasing hormone agonist, reduces gonadotropin and estrogen levels and is commonly used to alleviate the symptoms of endometriosis. Vitamin D3 has been reported to exhibit anti-inflammatory and pro-apoptotic …
Endometriosis is a common chronic disease in women of reproductive age, and long-term postoperative medical management is a key strategy for preventing recurrence. Currently used clinical medications include dienogest (DNG), …
Oxidative stress, defined as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, plays a critical role in female reproductive health, particularly in ovarian function. This review provides …
This study aimed to compare the clinical histories and clinicopathological characteristics between internal and external adenomyosis (ADM) among infertile women. A total of 759 infertile patients aged 24 to 40 …
Patient-derived organoids (PDOs) have emerged as physiologically relevant three-dimensional (3D) culture systems that closely mimic the molecular and histological features of the human endometrium and associated malignancies. Owing to their …
Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen …